MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Multiple Myeloma Research and Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,397 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,397 works in the cohort · of 4,299,418page 30 of 48

Labels cover 1 of 2,397 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,397 of 2,397 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Recurrent Anterior Skull Base Plasmocytoma
Ziv Gil, Jacob T. Cohen, Sergei Spektor, Leonor Leider–Trejo, Dan M. Fliss, Nigel Beasley +4 more
2002· article· en· Skull base· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
A34 DARATUMUMAB DOSE DEPENDENT LIVER INJURY
Mansour Altuwaijri, Eric Lam
2018· article· en· Journal of the Canadian Association of Gastroenterology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
The Role of CELMoD Agents in Multiple Myeloma
Nizar J. Bahlis, Charlotte Pawlyn, Francesca Gay, María‐Victoria Mateos, Katja Weisel, Sagar Lonial +1 more
2025· article· en· OncoTargets and Therapy· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affaboutunlabeled
Efficacy and Tolerance of Isatuximab, Cyclophosphamide, Bortezomib, and Dexamethasone (Isa-CBD) Induction Chemotherapy in Newly Diagnosed, Transplant Eligible Multiple Myeloma: Report of the Phase 2 Multi-Centre, Open Label Canadian Myeloma Research Group (CMRG)-008 Prospective Clinical Trial
Rami Kotb, Darrell White, Sita Bhella, Arleigh McCurdy, Irwindeep Sandhu, Hira Mian +6 more
2023· article· en· Blood· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.
María‐Victoria Mateos, Paweł Robak, Marek Hus, Chengcheng Fu, Vera Zherebtsova, Christopher Wård +13 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About